Adaptimmune Therapeutics plc (NASDAQ:ADAP) currently has a daily average trading volume of 506.43K but it saw 926622 shares traded on Thursday. With a market cap of 210.76M USD, stock’s current market price of $1.20 came rising about 6.19 while comparing to the previous closing price of $1.13. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.65 and as low as $1.01. In the recent trading on the day, stock has struck highest price mark of $1.26 while lowest mark touched by it was $1.10.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Taking a look at 20-day trading activity of Adaptimmune Therapeutics plc (ADAP) gives us an average price of $1.4620, while its current price level is -54.72% below from 52-week high level whereas it is 18.81% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.6458 while that of 200 days or SMA-200 reads an average of $1.6965. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.83% during that period while stretching the period over a month that increases to 8.86%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.55 which implies that the stock is in neutral territory.
Data by FactSet Research shows that 8 analysts have issued their ratings for the stock. 1 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 4 analysts suggested the investors to Buy the stock while 3 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Overweight for the stock and that issued by Wall Street to investors is Moderate Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Guggenheim which upgraded the stock as “Buy” in its note to investors issued on January 03, 2023, recommending a price target of $5 for it. Mizuho upgraded its recommendation for the stock as a “Buy” from “Neutral” on November 09, 2022 while assigning a price target of $9. Barclays issued its recommendations for the stock as it initiated the price target for the stock is $4.
Over the week, ADAP’s stock price is moving 0.84% up while it is -27.71% when we observe its performance for the past one month. Year-to-date it is -17.81% down and over the past year, the stock is showing a downside performance of -30.64%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of -$0.24 beat the consensus estimate of -$0.24 for the same. For ADAP, analysts are forecasting an EPS-growth rate of -7.80% for current year and estimate for EPS growth in next year is 29.10%. In next quarter, company is expected to be making quarterly sales of $3.9 million as analysts are expecting the sales for current fiscal year at $20.23 million and seeing the company making $20.72 million in sales next year. Moreover, analysts are in estimates of $4.12 million for current-quarter revenue.
Currently, Adaptimmune Therapeutics plc’s total number of outstanding shares is 165.31M with 0.12% of that held by the insiders while 70.15% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -203.30% and return on equity (ROE) at -132.30%. Stock’s beta reads 2.35. Stock has a price to book (P/B) ratio of 2.40 while price to sale or P/S ratio amounts to 7.78. Its return on asset (ROA) is -45.00% on average.
As per SEC documents, Baillie Gifford Overseas Growth F sought 6,056,564 of company’s common stock of worth $10.72 million as per recent closing price of the stock. Baillie Gifford Overseas Growth F is not the only institutional holder which restructured its stake in Adaptimmune Therapeutics plc, as Edinburgh Worldwide Investment Tr picked 4,678,397 shares of worth $8.28 million to bring its holdings to a total of 0.36 million shares. In the most recent quarter, Old Westbury Small & Mid Cap Stra came cutting its stake by -26.62% in the company and now holds 1.78 million or 1.09% of the company’s stake having worth of about 3.15 million.
Leave a Reply